Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

Migraine Clinical Trial

Official title:

Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04592952
• Other study ID #: H-20047793
• Status: Recruiting
• Phase: Phase 4
• Start date: October 8, 2020
• Est. completion date: August 1, 2025

Study information

• Verified date: October 2022
• Source: Danish Headache Center
• Contact: Messoud Ashina, MD
• Phone: +4538633385
• Email: ashina[@]dadlnet.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the relationship between clinical response to erenumab and response to intravenous infusion of calcitonin gene-related peptide in individuals with migraine.

Description:

This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab. The study will consist of the following elements: - Provocation Phase (1 experimental day with intravenous infusion of calcitonin gene-related peptide) - Screening/Baseline Phase (4 weeks) - Open-Label Treatment Phase (24 weeks)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: August 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Age = 18 years of age upon entry into screening
• History of migraine with or without aura for = 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria
• = 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening
• Subject has provided informed consent prior to initiation of any study-specific activities/procedures.
• Must have demonstrated greater than or equal to 75% compliance in Headache Diary usage during the 4-week run-period prior to Day 1 of the open-label treatment phase.

Exclusion Criteria:

• > 50 years of age at migraine onset
• History of cluster headache or hemiplegic migraine
• Inability to differentiate migraine from other headaches
• The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
• History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
• Previously received erenumab (Aimovig)
• Received anti-CGRP monoclonal antibody within 3 months prior to the CGRP-infusion
• Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
• Female subjects of childbearing potential with a positive pregnancy test during any study visit
• Female subject is pregnant or breastfeeding or planning to become pregnant during the study
• Evidence of current pregnancy or breastfeeding
• Female subject of childbearing potential unwilling to use an acceptable method of effective contraception
• Hypertension on the experimental day defined as systolic blood pressure = 150mmHg or diastolic blood pressure = 100mmHg
• Hypotension on the experimental day defined as systolic blood pressure < 90mmHg or diastolic blood pressure < 50mmHg
• Any headache (including migraine) within 24 hours prior to the start of the CGRP-infusion
• Intake of any analgesics or migraine-specific medications within 24 hours prior to the start of the CGRP-infusion
• Subject likely to not be available to complete all protocol-required study visits or procedures, and/or comply with all required study procedures to the best of the subject and study investigator's knowledge

Related Conditions & MeSH terms

• Hypersensitivity
• Migraine
• Migraine Disorders

Intervention

Drug:
• Calcitonin Gene-Related Peptide
Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
• Erenumab
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)

Locations

Country	Name	City	State
Denmark	Danish Headache Center	Copenhagen	Glostrup

Sponsors (1)

Lead Sponsor	Collaborator
Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Headache Diary (Baseline Phase and Treatment Phase)	Headache diary with daily entries to record migraine-related data (e.g. migraine days, headache days, number of days with use of acute migraine medication, number of days with aura).	Baseline Phase (Day -28 to Day 1) to Week 24
Secondary	Headache Diary (Provocation Phase)	Subjects will be instructed to fill out a headache diary during the 12-hour observational period. The diary will be used to record migraine-related data (e.g. location, quality, intensity, aggravation by routine physical activity, use of acute migraine medication, nausea, vomiting, photophobia, and phonophobia)	Provocation Phase (12 Hours)
Secondary	Semi-Structured Interview	In-person semi-structured interview to record migraine-related data (e.g. location, quality, intensity, aggravation by routine physical activity, use of acute migraine medication, nausea, vomiting, photophobia, phonophobia, premonitory symptoms, postdromal symptoms, trigger factors, autonomic symptoms).	1 Hour